Hemophagocytic syndrome secondary to SARS-Cov-2 infection : a case report
© 2021. The Author(s)..
BACKGROUND: Hemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient's recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection.
CASE PRESENTATION: We describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib.
CONCLUSIONS: Our report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 21(2021), 1 vom: 13. Aug., Seite 811 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meazza Prina, Marco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 31.08.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-021-06532-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329327496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329327496 | ||
| 003 | DE-627 | ||
| 005 | 20231225204856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-021-06532-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329327496 | ||
| 035 | |a (NLM)34388982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meazza Prina, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hemophagocytic syndrome secondary to SARS-Cov-2 infection |b a case report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 31.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Hemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient's recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection | ||
| 520 | |a CASE PRESENTATION: We describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib | ||
| 520 | |a CONCLUSIONS: Our report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Hemophagocytic syndrome | |
| 650 | 4 | |a Polyserositis | |
| 700 | 1 | |a Martini, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Bracchi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Di Mauro, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Fargnoli, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Motta, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Giussani, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Gobbin, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Taverna, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessio, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 21(2021), 1 vom: 13. Aug., Seite 811 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:13 |g month:08 |g pages:811 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-021-06532-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 13 |c 08 |h 811 | ||